DiaSorin stock slips as ransomware claim and FTSE MIB exit weigh on sentiment

Published on 09/04/2026 at 15:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

DiaSorin stock is trading slightly lower on September 4, 2026, as investors digest a reported ransomware claim against the company and its upcoming removal from the FTSE MIB index, despite broadly positive expectations for the biotech group.

Techniker im Reinraum bedienen automatisierte Diagnostikgeräte in modernem Biotech-Labor — Modernes Diagnostiklabor von DiaSorin S.p.A., ISIN IT0003497168, zeigt präzise Biotech-Produktion und klinische Fertigung, Illustration mit AI erstellt.

DiaSorin S.p.A. stock (ISIN IT0003497168) is trading modestly lower on September 4, 2026, with the shares quoted around 75.96 EUR in Milan, down about 1.04% intraday according to market data from Teleborsa and Borsa Italiana.

Index change and cyber incident shape the mood

According to a recent corporate news overview, DiaSorin is set to be replaced in the FTSE MIB index by Technoprobe, reducing its weight in Italy's blue chip benchmark and prompting repositioning by index-focused investors. Market data compiled by Borsa Italiana for September 3, 2026, showed DiaSorin shares at a last value of 76.22 EUR with a price at 75.84 EUR earlier in the session and a daily change of about plus 0.50%, indicating a modest gain before the latest pullback.

Sentiment has also been affected by cybersecurity headlines. On September 3, 2026, ransomware group Settra claimed responsibility for an attack on DiaSorin's infrastructure, specifically referencing the int.diasorin.com domain, as reported by DeXpose cybersecurity monitors. A separate breach listing published on September 3, 2026 and reviewed on September 4, 2026 by GalaxyWarden reiterates that the int.diasorin.com host was included on Settra's list, reinforcing the perception of a targeted cyber incident.

Short-term trading signals and recent price levels

Intraday on September 4, 2026, Teleborsa data show DiaSorin changing hands at around 75.96 EUR, with the session's low and high reported near 75.70 EUR and 77.38 EUR respectively, pointing to a trading range of about 1.68 EUR on the day.

A trading commentary published by Teleborsa on September 4, 2026 highlights that DiaSorin is seen with positive expectations, describing the shares as suitable for purchase at a level of about 76.76 EUR with an indicative stop loss at 73.56 EUR. This implies a potential short-term upside of roughly 3.20 EUR from the stop level to the suggested entry point, a difference of about 4.3% based on these reference prices. For retail investors, such trading signals underline that the stock is currently being watched not only for fundamentals but also for tactical opportunities in a volatile environment.

Recent quote histories compiled by MarketScreener show a closing price of 76.08 EUR for DiaSorin on September 3, 2026 and 73.75 EUR on September 1, 2026, indicating a gain of about 2.33 EUR or approximately 3.2% over these two sessions. Over the last five trading days, MarketScreener data cite a performance of about plus 2.55% for the shares, and a gain of around 12.63% over a longer comparison window, signalling that the current intraday weakness comes after a period of appreciation.

Go deeper

More on DiaSorin stock and fundamentals

Investors can follow detailed news, regulatory filings and additional figures for DiaSorin stock directly via the DIA SORIN themed overview and the company's Investor Relations portal.

DiaSorin stock on ad-hoc-news.de Investor Relations

Diagnostics portfolio supports the investment case

DiaSorin is a specialty diagnostics company focusing on immunodiagnostics and molecular diagnostics for infectious diseases, oncology and other clinical areas. Its product range includes reagents and instruments used by hospital and laboratory customers to run tests for conditions such as hepatitis, HIV and other viral and bacterial infections, helping clinicians make timely treatment decisions.

A representative product segment is its molecular diagnostics platform for respiratory pathogens, which contributes to revenue by providing test panels for viruses like influenza and other respiratory agents. Historically, DiaSorin reported that pandemic-related testing had boosted demand in earlier years; investors now pay attention to how the mix shifts towards routine testing and specialized assays as emergency volumes normalise. While up-to-date segment revenue figures for fiscal year 2025 or the latest half-year are not explicitly visible in the current day-filtered search results, the company's established presence in high-value diagnostics supports the longer-term investment narrative.

DiaSorin stock near recent highs in Milan

DiaSorin is listed on Borsa Italiana and included in Italy's FTSE MIB index until its upcoming replacement, with the shares traded in EUR under the ticker typically cited as DIA. Based on Teleborsa and MarketScreener data, the latest completed closing price stands at 76.08 EUR as of September 3, 2026 on the Milan exchange. As of intraday trading on September 4, 2026, the stock is quoted at about 75.96 EUR, placing it slightly below that most recent closing level.